2 completed, 2 recruiting, 1 active not recruiting, 1 unknown. 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow InnoCare Pharma Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL Orelabrutinib, Zuberitamab, Cyclophosphamide - Marginal Zone Lymphoma(MZL) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 65 | 2025-10-01 | 2026-04-02 |
| Phase I Study of ICP-332 in Healthy Subjects ICP-332 Tablets, ICP-332 Placebo Tablets - Healthy Subjects | Phase 1 | Completed | InnoCare Pharma Inc. | 24 | 2024-07-23 | 2026-04-14 |
| A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL Orelabrutinib, Bendamustine Injection, Rituximab - Mantle Cell Lymphoma | Phase 3 | Recruiting | InnoCare Pharma Inc. | 476 | 2024-05-29 | 2024-12-27 |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies ICP-248, Obinutuzumab (G), Rituximab (R) - Mature B-cell Malignancies | Phase 1 | Recruiting | InnoCare Pharma Inc. | 78 | 2024-04-23 | 2025-06-19 |
| Evaluating Different Doses of Orelabrutinib in MCL Orelabrutinib High dose, Orelabrutinib Low dose - Mantle Cell Lymphoma | Phase 2 | Completed | InnoCare Pharma Inc. | 40 | 2023-08-18 | 2026-06-11 |
| Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors ICP-723 - Advanced Solid Tumors | Phase 1 | Unknown | InnoCare Pharma Inc. | 30 | 2021-07-30 | 2023-01-20 |
Lymphoma, Mantle-Cell (2) · Lymphoma, B-Cell, Marginal Zone (1)
orelabrutinib (3) · Rituximab (2) · Bendamustine Hydrochloride (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Vincristine (1) · obinutuzumab (1)
China (3) · United States (3) · Puerto Rico (1) · Ukraine (1)
Jun Zhang (1) · Xinxin Cao, doctor (1)